2-[(4'-tert-butylbiphenyl-2-carbonyl)amino]quinoline-6-carboxylic acid | 863492-41-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-[(4'-tert-butylbiphenyl-2-carbonyl)amino]quinoline-6-carboxylic acid
• 英文别名: 2-[[2-(4-Tert-butylphenyl)benzoyl]amino]quinoline-6-carboxylic acid
• CAS: 863492-41-5
• 化学式: C₂₇H₂₄N₂O₃
• 分子量: 424.499
• InChiKey: AGFMMTRGWVRFIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(4'-tert-butylbiphenyl-2-carbonyl)amino]quinoline-6-carboxylic acid 、 (S)-2-amino-N-(4-fluorobenzyl)-N-methyl-2-phenylacetamide hydrochloride 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以82%的产率得到(S)-2-[(4'-tert-butyl-biphenyl-2-carbonyl)-amino]-quinoline-6-carboxylic acid {[(4-fluoro-benzyl)-methyl-carbamoyl]-phenyl-methyl}-amide
  参考文献：
  名称：

  [EN] SUBSTITUTED QUINOLINE COMPOUNDS
  [FR] COMPOSES DE QUINOLINE SUBSTITUES

  摘要：

  本发明涉及式(I)的MTP/Apo-B分泌抑制剂，其中R1-R7、X1、m和n的定义如说明书中所述，以及包含这些化合物的药物组合物，以及这些化合物和组合物的使用方法。本发明的化合物可用于治疗肥胖及其相关疾病、状况或失调。

  公开号：

  WO2005080373A1
• 作为产物：
  描述：

  2-氨基喹啉-6-甲酸苄酯 在 4-二甲氨基吡啶 、 lithium hydroxide monohydrate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 生成 2-[(4'-tert-butylbiphenyl-2-carbonyl)amino]quinoline-6-carboxylic acid
  参考文献：
  名称：

  Discovery of microsomal triglyceride transfer protein (MTP) inhibitors with potential for decreased active metabolite load compared to dirlotapide

  摘要：

  Analogues related to dirlotapide (1), a gut-selective inhibitor of microsomal triglyceride transfer protein (MTP) were prepared with the goal of further reducing the potential for unwanted liver MTP inhibition and associated side-effects. Compounds were designed to decrease active metabolite load: reducing MTP activity of likely human metabolites and increasing metabolite clearance to reduce exposure. Introduction of 4'-alkyl and 4'-alkoxy substituents afforded compounds exhibiting improved therapeutic index in rats with respect to liver triglyceride accumulation and enzyme elevation. Likely human metabolites of select compounds were prepared and characterized for their potential to inhibit MTP in vivo. Based on preclinical efficacy and safety data and its potential for producing short-lived, weakly active metabolites, compound 13 (PF-02575799) advanced into phase 1 clinical studies. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.05.099

文献信息

• [EN] 1,4-DIHYDRONAPHTHYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,4-DIHYDRONAPHTYRIDINE
  申请人：PFIZER PROD INC

  公开号：WO2009056934A1

  公开（公告）日：2009-05-07

  A compound of formulae (I) or a prodrug of the compound or a pharmaceutically acceptable salt thereof of the compound or prodrug, wherein the substituents are as defined in the specification, pharmaceutical compositions containing the compounds useful as calcium channel antagonists, and to methods of treating heart disease and pain.

  一种化合物的公式（I）或该化合物的前药或其药用可接受的盐或前药，其中取代基如规范中所定义，含有该化合物的药用组合物可用作钙通道拮抗剂，并用于治疗心脏病和疼痛的方法。
• Diaryl Ether Derivatives and Uses Thereof
  申请人：Ruggeri B. Roger

  公开号：US20080070887A1

  公开（公告）日：2008-03-20

  Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. where R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are described herein.

  本文描述了具有化学式（I）的化合物，这些化合物在mu、kappa和/或delta阿片受体上起拮抗作用，因此在动物治疗受益于这种拮抗作用的疾病、状况和/或障碍方面具有用处。其中R1、R2、R3、R4、R5和R6如下描述。
• Substituted quinoline compounds
  申请人：Bertinato Peter

  公开号：US20050234099A1

  公开（公告）日：2005-10-20

  This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R 1 -R 7 , X 1 , m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

  本发明涉及公式（I）中的MTP / Apo-B分泌抑制剂，其中R1-R7，X1，m和n如规范中所定义，以及包含该化合物的制药组合物，以及该化合物和组合物的使用方法。本发明的化合物在治疗肥胖和相关疾病，状况或障碍方面是有用的。
• TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS
  申请人：Bertinato Peter

  公开号：US20060223851A1

  公开（公告）日：2006-10-05

  This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R 1 -R 7 , X 1 , m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

  本发明涉及公式（I）中的MTP / Apo-B分泌抑制剂，其中R1-R7，X1，m和n如规范中定义，以及包含该化合物的制药组合物和该化合物和组合物的使用方法。本发明的化合物在治疗肥胖及其相关疾病，情况或障碍方面有用。
• Triamide-substituted heterobicyclic compounds
  申请人：Bertinato Peter

  公开号：US20070093525A1

  公开（公告）日：2007-04-26

  This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R 1 -R 7 , X 1 , m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

  本发明涉及公式(I)中的MTP / Apo-B分泌抑制剂，其中R1-R7，X1，m和n如说明书中所定义，以及包含该化合物的制药组合物，以及使用该化合物和组合物的方法。该发明的化合物对于治疗肥胖症及其相关疾病、病况或障碍具有用途。